PUBLICATIONS
ORIGINALS
Should patients with NAFLD/NASH be surveyed for HCC?

Reig M
, Gambato M, Man NK, Roberts JP, Victor D, Orci LA, Toso C

Transplantation 2018;:doi: 10.1097/TP.0000000000002361
Pubmed abstract

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase 3 RESORCE trial.

Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, 
Bruix J J Hepatology 2018;:10.1016/j.jhep.2018.04.010
Pubmed abstract

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma.

Tutusaus A, Stefanovic M, Boix L, Cucarull B, Zamora A, Blasco L, de Frutos PG, Reig M, Fernandez-Checa JC, Marí M, Colell A, 
Bruix J, Morales A. Oncotarget 2018;24:16701-16717
Pubmed abstract

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, 
Bruix J. Lancet Oncol 2018;5:682-693
Pubmed abstract

Complete response under sorafenib in patients with hepatocellular carcinoma. Relationship with dermatologic adverse events

Rimola J
, Díaz-González Á, Darnell A, Varela M, Pons F, Hernandez-Guerra M, Delgado M, Castroagudin J, Matilla A, Sangro B, de Lope CR, Sala M, Gonzalez C, Huertas C, Minguez B, Ayuso C, Bruix J, Reig M
Hepatology 2017;
Pubmed abstract

Trunk events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma

Torrecilla S, Sia D, Harrington AN, Zhang Z, Cabellos L, Cornella H, Moeini A, Camprecios G, Leow WQ, Fiel MI, Hao K, Bassaganyas L, Mahajan M, Thung SN, Villanueva A, Florman S, Schwartz ME, Llovet JM J Hepatol 2017;
Pubmed abstract

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet JM Gastroenterology 2017;
Pubmed abstract

Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma

Urtasun N, Boces-Pascual C, Boix L, 
Bruix J, Pastor-Anglada M, Pérez-Torras S Oncotarget 2017;8:90185-90196
Pubmed abstract

Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results
Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM Eur Radiol 2017;
Pubmed abstract

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Dr Jordi Bruix
, MD, Prof Shukui Qin, MD, Prof Philippe Merle, MD, Alessandro Granito, MD, Prof Yi-Hsiang Huang, MD, György Bodoky, MD, Marc Pracht, MD, Prof Osamu Yokosuka, MD, Prof Olivier Rosmorduc, MD, Valeriy Breder, MD,
The Lancet 2016;
Pubmed abstract

Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication
Coto-Llerena M, Koutsoudakis G, Boix L, López-Oliva JM, Caro-Pérez N, Fernández-Carrillo C, González P, Gastaminza P, Bruix J, Forns X, Pérez-Del-Pulgar S Virus Res 2017;
Pubmed abstract

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
Bruix J
, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J
 
J Hepatol 2017;
Pubmed abstract

Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma

Solms A, Reinecke I, Fiala-Buskies S, Keunecke A, Drenth HJ, 
Bruix J, Meinhardt G, Cleton A, Ploeger B
Eur J Pharm Sci 2017;
Pubmed abstract

Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment

Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J

 
Hepatology 2016;64:1178-88
Pubmed abstract

The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma
Reig M, Boix L, Bruix J

Liver International 2017;1:136-139
Pubmed abstract

Restoring mir122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through smad-independent TGF-β pathway

Boix L, López-Oliva JM, Rhodes AC, Bruix J Oncotarget 2016;
Pubmed abstract

Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution.

Reig, M
, Mariño, Z, Perelló, C, Iñarrairaegui, M, Ribeiro, A, Lens, S, Díaz, A, Vilana, R, Darnell, A, Varela, M, Sangro, B, Calleja, J.L, Forns, X, Bruix, J

Journal of Hepatology 2016;:doi: 10.1016/j.jhep.2016.04.008
Pubmed abstract

Sorafenib or Placebo plus TACE with Doxorubicin-Eluting Beads for Intermediate-Stage HCC: Phase II, Randomized, Double-Blind SPACE Trial.
Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J.

Journal of Hepatology 2016;:doi: 10.1016/j.jhep.2016.01.012
Pubmed abstract

Prospective validation of "ab initio" liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection.
Ferrer-Fàbrega J, Forner A, Liccioni A, Miquel R, Molina V, Navasa M, Fondevila C, García-Valdecasas JC, 
Bruix J, Fuster J. Hepatology 2015;doi: 10.1002/hep.28339
Pubmed abstract

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre ML, Meinhardt G, Llovet JM; STORM investigators.

Lancet Oncol. 2015 ;Sep 8. :pii: S1470-2045(15)00198-9. doi: 10.1016/S1470-2045(15)00198-9.
Pubmed abstract

Progenitor cell markers predict outcome of patients with Hepatocellular Carcinoma beyond Milan criteria undergoing liver transplantation. Miltiadous O, Sia D, Hoshida Y, Fiel MI, Harrington AN, Thung SN, Tan PS, Dong H, Revill K, Chang CY, Roayaie S, Byrne TJ, Mazzaferro V, Rakela J, Florman S, Schwartz M, Llovet JM. J Hepatol. 2015;Jul 25. :pii: S0168-8278(15)00516-4. doi: 10.1016/j.jhep.2015.07.025.
Pubmed abstract

Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. Darnell A, Forner A, Rimola J, Reig M, García-Criado Á, Ayuso C, Bruix J. Radiology. 2015;Jun:275(3):698-707.
Pubmed abstract

A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.

Zhang DY, Goossens N, Guo J, Tsai MC, Chou HI, Altunkaynak C, Sangiovanni A, Ivarone M, Colombo M, Kobayashi M, Kumada H, Villanueva A, Llovet JM, Hoshida Y, Friedman SL.

Gut. 2015;Jun 4:pii: gutjnl-2015-309655
Pubmed abstract

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J. Nat Genet. 2015;Mar 30.:doi: 10.1038/ng.3252.
Pubmed abstract

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak CA, Nagle JM, Perera RM, Lapouge M, Deshpande V, Zhu AX, Lai A, Min B, Hoshida Y, Avruch J, Sia D, Campreciós G, McClatchey AI, Llovet JM, Morrissey D, Raj L, Bardeesy N. Cell Rep. 2015;Mar 10. :doi: 10.1016/j.celrep.2015.02.027.
Pubmed abstract

Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Hepatology. 2015;Feb;:61(2):526-36.
Pubmed abstract

Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. Darnell A, Forner A, Rimola J, Reig M, García-Criado Á, Ayuso C, Bruix J. Radiology. 2015;Feb 5::141132.
Pubmed abstract

DNA Methylation-based prognosis and epidrivers in hepatocellular carcinoma. Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Méndez-González J, Imbeaud S, Letouzé E, Hernandez-Gea V, Cornella H, Pinyol R, Solé M, Fuster J, Zucman-Rossi J, Mazzaferro V, Esteller M, Llovet JM; on behalf of the HEPTROMIC Consortium. Hepatology. 2015;Feb 2.
Pubmed abstract

Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2cm. Forner A, Vilana R, Bianchi L, Rodríguez-Lope C, Reig M, García-Criado MÁ, Rimola J, Solé M, Ayuso C, Bru C, Bruix J. J Hepatol. 2015;Jan;:62(1):150-5.
Pubmed abstract

Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, Bonal D, Miltiadous O, Zhang Z, Hoshida Y, Cornella H, Castillo-Martin M, Pinyol R, Kasai Y, Roayaie S, Thung SN, Fuster J, Schwartz ME, Waxman S, Cordon-Cardo C, Schadt E, Mazzaferro V, Llovet JM. Nat Commun. 2015;Jan 22;:6:6087.
Pubmed abstract

Unique genomic profile of fibrolamellar hepatocellular carcinoma. Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, Hoshida Y, Villanueva A, Thung S, Ward SC, Rodriguez-Carunchio L, Vila-Casadesús M, Imbeaud S, Lachenmayer A, Quaglia A, Nagorney DM, Minguez B, Carrilho F, Roberts LR, Waxman S, Mazzaferro V, Schwartz M, Esteller M, Heaton ND, Zucman-Rossi J, Llovet JM. Gastroenterology. 2014;Dec 31. :pii: S0016-5085(14)01580-7.
Pubmed abstract

Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience. de la Serna S, Vilana R, Sánchez-Cabús S, Calatayud D, Ferrer J, Molina V, Fondevila C, Bruix J, Fuster J, García-Valdecasas JC. HPB (Oxford). 2014;Dec 29.
Pubmed abstract

SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK. J Clin Oncol. 2014;Dec 29. :pii: JCO.2013.53.7746.
Pubmed abstract

Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer. Barbier-Torres L, Delgado TC, García-Rodríguez JL, Zubiete-Franco I, Fernández-Ramos D, Buqué X, Cano A, Gutiérrez-de Juan V, Fernández-Domínguez I, Lopitz-Otsoa F, Fernández-Tussy P, Boix L, Bruix J, Villa E, Castro A, Lu SC, Aspichueta P, Xirodimas D, Varela-Rey M, Mato JM, Beraza N, Martínez-Chantar ML. Oncotarget. 2014;Dec 11.
Pubmed abstract

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N. Nature. 2014;Sep 4;:513(7516):110-4.
Pubmed abstract

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. Reig M, Torres F, Rodriguez-Lope C, Forner A, LLarch N, Rimola J, Darnell A, Ríos J, Ayuso C, Bruix J. J Hepatol. 2014;Aug;:61(2):318-24.
Pubmed abstract

A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan PS, Sun X, Villanueva A, Sangiovanni A, Nair V, Mahajan M, Kobayashi M, Kumada H, Iavarone M, Colombo M, Fiel MI, Friedman SL, Llovet JM, Chung RT, Hoshida Y. Gut. 2014;Aug 20. :pii: gutjnl-2014-307862.
Pubmed abstract

Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine Mingorance L, Friesland M, Coto-Llerena M, Pérez-del-Pulgar S, Boix L, López-Oliva JM, Bruix J, Forns X, Gastaminza P. Antimicrob Agents Chemother. 2014 ;Jun:61(2):318-24.
Pubmed abstract

UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma.

Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson RT, Lachenmayer A, Revill K, Alsinet C, Sachidanandam R, Desai A, Senbanerjee S, Ukomadu C, Llovet JM, Sadler KC.

Cancer Cell. 2014;Feb 10;:25(2):196-209
Pubmed abstract

Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Patients Undergoing Liver Transplantation: A Spanish Matched Cohort Multicenter Study.

Sapisochin G, de Lope CR, Gastaca M, de Urbina JO, López-Andujar R, Palacios F, Ramos E, Fabregat J, Castroagudín JF, Varo E, Pons JA, Parrilla P, González-Diéguez ML, Rodriguez M, Otero A, Vazquez MA, Zozaya G, Herrero JI, Antolin GS, Perez B, Ciria R, Rufian S, Fundora Y, Ferron JA, Guiberteau A, Blanco G, Varona MA, Barrera MA, Suarez MA, Santoyo J, Bruix J, Charco R.

Ann Surg. 2014;Jan 16.
Pubmed abstract

"Very Early" Intrahepatic Cholangiocarcinoma in Cirrhotic Patients: Should Liver Transplantation Be Reconsidered in These Patients?

Sapisochin G, Rodríguez de Lope C, Gastaca M, Ortiz de Urbina J, Suarez MA, Santoyo J, Castroagudín JF, Varo E, López-Andujar R, Palacios F, Sanchez Antolín G, Perez B, Guiberteau A, Blanco G, González-Diéguez ML, Rodriguez M, Varona MA, Barrera MA, Fundora Y, Ferron JA, Ramos E, Fabregat J, Ciria R, Rufian S, Otero A, Vazquez MA, Pons JA, Parrilla P, Zozaya G, Herrero JI, Charco R, Bruix J.

Am J Transplant. 2014;Jan 10. :doi: 10.1111/ajt.12591.
Pubmed abstract

Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner A, Llarch N, Ríos J, Ayuso C, Bruix J. Hepatology. 2013;Dec;:58(6):2023-31.
Pubmed abstract

Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma.

Revill K, Wang T, Lachenmayer A, Kojima K, Harrington A, Li J, Hoshida Y, Llovet JM, Powers S.

Gastroenterology. 2013;Dec;:145(6):1424-35.e1-25.
Pubmed abstract

Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.

Finn RS, Poon RT, Yau T, Klümpen HJ, Chen LT, Kang YK, Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J.

J Hepatol. 2013;Dec;:59(6):1271-7.
Pubmed abstract

A DNA methylation signature associated with the epigenetic repression of glycine N-methyltransferase in human hepatocellular carcinoma.

Huidobro C, Toraño EG, Fernández AF, Urdinguio RG, Rodríguez RM, Ferrero C, Martínez-Camblor P, Boix L, Bruix J, García-Rodríguez JL, Varela-Rey M, Mato JM, Martínez-Chantar ML, Fraga MF.

J Mol Med (Berl). 2013;Aug;:91(8):939-50.
Pubmed abstract

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I,Park JW. J Clin Oncol. 2013;Aug 26
Pubmed abstract

A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Nault JC, De Reyniès A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, Azoulay D, Saric J, Blanc JF, Balabaud C, Bioulac-Sage P, Laurent A, Laurent-Puig P, Llovet JM, Zucman-Rossi. J.Gastroenterology 2013;Jul;145(1):176-87
Pubmed abstract

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L. Eur J Cancer. 2013;Jun 25
Pubmed abstract

Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design. Reig M, Rimola J, Torres F, Darnell A, Lope CR, Forner A, Llarch N, Ríos J, Ayuso C, Bruix J Hepatology 2013;Jun 20
Pubmed abstract

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET- Letter. Rimassa L, Bruix J, Broggini M, Santoro A Clin Cancer Res. 2013;Jun 13
Pubmed abstract

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC,Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM.

Gastroenterology. 2013;Apr;:144(4):829-40.
Pubmed abstract

Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.

Poynard T, Bruix J, Schiff ER, Diago M, Berg T, Moreno-Otero R, Lyra AC, Carrilho F, Griffel LH, Boparai N, Jiang R, Burroughs M, Brass CA, Albrecht JK.

J Hepatol. 2013;Mar;:58(3):452-9.
Pubmed abstract

Prognostic Gene Expression Signature for Patients With Hepatitis C-Related Early-Stage Cirrhosis Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Gastroenterology 2013;Jan 17
Pubmed abstract

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Santoro A, Simonelli M, Rodriguez-Lope C, Zucali P, Camacho LH, Granito A, Senzer N, Rimassa L, Abbadessa G, Schwartz B, Lamar M, Savage RE, Bruix J. Br J Cancer. 2013;Jan 15
Pubmed abstract

Resection of hepatocellular cancer ≤2 cm: Results from two Western centers. Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M, Mazzaferro V. Hepatology 2013;Apr
Pubmed abstract

Short-chain PEG molecules strongly bound to magnetic nanoparticle for MRI long circulating agents. Ruiz A, Salas G, Calero M, Hernández Y, Villanueva A, Herranz F, Veintemillas-Verdaguer S, Martínez E, Barber DF, Morales MP. Acta Biomaterialia 2013;May
Pubmed abstract

Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, Rodriguez-Carunchio L, Solé M, Thung S, Stanger BZ, Llovet JM. Gastroenterology 2012;Dec
Pubmed abstract

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. J Hepatol. 2012 Oct;57(4):821-829.
Pubmed abstract

Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM. Clin Cancer Res. 2012 Sep 15;18(18)::4997-5007.
Pubmed abstract

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J; SHARP Investigators Study Group. Clin Cancer Res. 2012;18:2290-2300.
Pubmed abstract

Non-invasive diagnosis of hepatocellular carcinoma 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. Rimola J, Forner A, Tremosini S, Reig M, Vilana R, Bianchi L, Rodriguez-Lope C, Solé M, Ayuso C, Bruix J. J Hepatol 2012;56:1317-1323.
Pubmed abstract

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using DCBeads. Implications for clinical practice and trial design. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J. J Hepatol. 2012 Jun;56(6):1330-5.
Pubmed abstract

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. Raoul JL, Bruix J, Greten TF, Sherman M, Mazzaferro V, Hilgard P, Scherubl H, Scheulen ME, Germanidis G, Dominguez S, Ricci S, Nadel A, Moscovici M, Voliotis D, Llovet JM. J Hepatol. 2012;56:1080-1088.
Pubmed abstract

Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Tremosini S, Forner A, Boix L, Vilana R, Bianchi L, Reig M, Rimola J, Rodríguez-Lope C, Ayuso C, Solé M, Bruix J. Gut. 2012;61:1481 – 1487.
Pubmed abstract

Induction of hepatocellular carcinoma by in vivo gene targeting. Wang PR, Xu M, Toffanin S, Li Y, Llovet JM, Russell DW. Proc Natl Acad Sci U S A 2012;Jul 10
Pubmed abstract

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, Friedman SL, Llovet JM. J Hepatol. 2012;Jun
Pubmed abstract

A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis. Paris AJ, Snapir Z, Christopherson CD, Kwok SY, Lee UE, Ghiassi-Nejad Z, Kocabayoglu P, Sninsky JJ, Llovet JM, Kahana C, Friedman SL. Hepatology 2011;Dec
Pubmed abstract

Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma. NN Massarweh, JO Park, J Bruix, R S W Yeung, RB Etzioni, RG Symons, LM Baldwin, DR Flum. J. Oncol. Pract. 2011;7:155-160.
Pubmed abstract

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC(•) program. T. Poynard, M Munteanu, M Colombo, J Bruix, E Schiff, R Terg, S Flamm, R Montero-Otero, F Carrilho, W Schmidt, T Berg, T McGarrity, EJ Heathcote, F Gonçales, M Diago, A Craxi, M Silva, N Boparai, L Griffel, M Burroughs, C Brass, J. Albrecht. J Hepatol. 2011;54:227-235
Pubmed abstract

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. A Villanueva, Y Hoshida, C Battiston, V Tovar, D Sia, C Alsinet, H Cornella, A liberzon, M Kobayashi, H Kumada, SN Thung, J Bruix, P Newell, C April, JB Fan, S Roayaie, V Mazzaferro, ME Schwartz, JM Llovet. Gastroenterology 2011;140:1501-1512.
Pubmed abstract

Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C. J Bruix, T Poymard, M Colombo, E Schiff, K Burak, EJ Healthcote, T Berq, JL Poo, CB Melllo, R Guenther, C Niederau, R Terg, P Bedossa, N Boparal LH Griffel, M Burroughs, CA Brass, JK Albrecht, Epic Study Group. Gastroenterology 2011;140:1990-1999.
Pubmed abstract

MicroRNA-Based classification of hepatocellular carcinoma and oncogenic role of miR-517a. S Toffanin, Y Hoshida, A Lachenmayer, A Villanueva, L Cabellos, B Minguez, R Savic, SC Ward, S Thung, DY Chiang, C Alsinet, V Tovar, S Rayaie, M Schwartz, J Bruix, S Waxman, SL Friedman, T Golub, V Mazzaferro, JM Llovet. Gastroenterology 2011;140:1618-1628.
Pubmed abstract

Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Llovet JM, Paradis V, Kudo M, Zucman-Rossi J. Liver Transpl 2011;Oct
Pubmed abstract

Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Tarocchi M, Hannivoort R, Hoshida Y, Lee UE, Vetter D, Narla G, Villanueva A, Oren M, Llovet JM, Friedman SL. Hepatology 2011;Aug
Pubmed abstract